Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aldeyra TherapeuticsALDX -1.94%29 3-Year EBITDA Growth Rate is 19.90% as of Mar. 2026, which is 129% above its 10-year median of 8.70. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,136 Biotechnology companies, Aldeyra Therapeutics ranks better than 56.34% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aldeyra Therapeutics was 34.90% per year. The lowest was -43.20% per year. And the median was 8.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aldeyra Therapeutics 3-Year EBITDA Growth Rate Related Terms
ALDX vs ONCY, VRCA, CUE: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Aldeyra Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.90% mean?
Aldeyra Therapeutics (ALDX) has a 3-Year EBITDA Growth Rate of 19.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aldeyra Therapeutics and its competitors. This is 129% above median its historical median of 8.70. According to the industry distribution chart, Aldeyra Therapeutics ranks #496 out of 1136 companies in the Biotechnology industry, placing it in the top 43.7%.
Is Aldeyra Therapeutics' 3-Year EBITDA Growth Rate too high?
Aldeyra Therapeutics' current 3-Year EBITDA Growth Rate of 19.90% is 129% above median its 10-year median of 8.70. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.95. Aldeyra Therapeutics' value of 19.90% is 33.1% above this industry median. Based on the distribution chart, Aldeyra Therapeutics ranks #496 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' 3-Year EBITDA Growth Rate compare to ONCY and VRCA?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #496 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Aldeyra Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.95. Aldeyra Therapeutics' value of 19.90% is 33.1% above this benchmark. While the company's 10-year median is 8.70 vs. the industry median of 14.95, Aldeyra Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.95, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aldeyra Therapeutics's current 3-Year EBITDA Growth Rate of 19.90% is 33.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aldeyra Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aldeyra Therapeutics's current 3-Year EBITDA Growth Rate is 19.90%, which is 129% above median its own 10-year median of 8.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current 3-Year EBITDA Growth Rate of 19.90%. The current 3-Year EBITDA Growth Rate is 19.90%, which is 129% above median its 10-year median of 8.70 and 33.1% above the Biotechnology industry median of 14.95. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current 3-Year EBITDA Growth Rate is 19.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score
Get the complete analysis for ALDX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALDX has been successfully added to your 
